Natick-based Boston Scientific plans to acquire Plymouth, Minn.-based Atritech Inc. for a total consideration of $375 million.
The deal includes an up-front payment of $100 million and potential payments of up to $275 million if certain regulatory and revenue benchmarks are met through 2015.
Atritech brings to Boston Scientific a medical device called the Watchman Left Atrial Appendage Closure Technology, which can be used in heart surgeries. The Watchman device has been used in an 800-patient randomized clinical trial and FDA approval is being sought.
Boston Scientific expects the transaction to close in the first quarter.
